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of nuclear proteins from Ang II-stimulated AT1 receptor trans-Angiotensin II activates nuclear transcription factor-B through
fected COS7 cells. An artificial peptide (p-Amino-Phe6-Ang II)AT1 and AT2 receptors.
with a high affinity for the AT2 receptor also activated NF-B.Background. Recent evidence suggests that angiotensin II
Ang II-induced activation of NF-B was associated with degra-(Ang II) induces a variety of proinflammatory mediators in-
dation of IB- in all studied cell lines.cluding chemokines. Nuclear factor-B (NF-B) activation
Conclusions. Our results clearly demonstrate in various cellplays an important role in Ang II-mediated inflammation. The
lines that Ang II induces NF-B activation through AT2 recep-present study investigated which Ang II receptor subtype is
tors. These data may have important therapeutic consequences,involved in NF-B activation. We focused particularly on the
because potential Ang II-mediated proinflammatory renal andAng II subtype 2 (AT2) receptor because we previously ob-
cardiovascular effects may not be totally antagonized by theserved that Ang II-induction of the chemokine RANTES in
vitro and in vivo is mediated through AT2 receptors. currently increased clinical use of AT1 receptor antagonists.
Methods. AT1 or AT2 receptors were selectively overex-
pressed in COS7 cells that normally do not express Ang II
receptors. In addition, rat glomerular endothelial cells (GER)
There is accumulating evidence that angiotensin IIthat express AT1 and AT2 receptors and PC12 cells that exclu-
(Ang II) is a pivotal pathophysiological factor in chronicsively exhibit AT2 receptors were studied also. Ang II-receptor
expression was confirmed by Western blots of membrane ly- renal disease [1–4]. Besides its well-known hemody-
sates. NF-B DNA binding in vitro was detected by electropho- namic actions, Ang II exerts growth stimulatory and pro-
retic shift assays. In addition, in vivo transactivation of a re- fibrogenic effects and even exhibits properties of an in-porter gene construct with  enhancer coupled to luciferase
flammatory factor [5–9]. In vascular smooth muscle cellsalso was investigated. Expression of the inhibitor of B alpha
(VSMC) and renal cells, including glomerular endothe-(IB-) was detected by Western blots.
Results. In AT1 or AT2 receptor transfected cells, but not un- lial and mesangial cells, Ang II induces chemokines such
transfected COS7 cells, 107 mol/L Ang II induced NF-B DNA as monocyte chemoattractant protein-1 (MCP-1) and reg-
binding in vitro, as detected by electrophoretic shift assays and ulated upon activation, normal T cell expressed and se-in vivo transactivation of a reporter gene construct. The AT2 creted (RANTES) expression [10–13]. Nuclear factor-Breceptor antagonist PD 123319 but not losartan attenuated
(NF-B) is a key transcription factor in inflammatoryAng II-mediated NF-B activation in COS7 cells transfected
with AT2 receptors. While Ang II also induced NF-B activa- diseases and stimulates, among other genes, the tran-
tion in PC12 cells, this activation was blocked by PD 123319. scription of chemokines [14, 15]. Ruiz-Ortega and asso-
Finally, stimulation of GERs with Ang II led to the activation ciates were the first demonstrating that Ang II couldof NF-B through both subtypes of Ang II receptors. Nuclear
activate NF-B in cultured mesangial cells and VSMCextracts from COS7 cells transfected with AT2 receptors and
[11, 16]. Although it is generally assumed that Ang IIPC12 cells with NF-B DNA-binding activity consisted of p50/
p65 complexes. There was no difference in subunit composition transduces its inflammatory properties through Ang II
subtype 1 (AT1) receptors and mice that lack AT1A recep-
tors reveal an attenuated immune response [8, 17, 18],
1 See Editorial by Luft, p. 2272. there is some evidence that AT2 receptors may play a
role. We found that Ang II infusion into rats stimulatesKey words: angiotensin II, AT2 receptors, nuclear factor-B, inflam-
mation. RANTES expression in glomerular endothelial cells [13].
This effect was attenuated by an AT2 receptor antagonist,Received for publication September 6, 2001
but not by losartan [13]. Furthermore, studies in VSMCand in revised form December 26, 2001
Accepted for publication January 24, 2002 also demonstrated that AT2-receptors play a role in Ang
II-induced NF-B activation [16]. However, since studies 2002 by the International Society of Nephrology
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with selective receptor antagonists could be difficult to the medium was changed and cells were incubated for
12 hours with control medium (serum-free DMEM) or ainterpret and there may be an interaction between AT1
and AT2 receptors, for the present study we chose a single dose of 107 mol/L Ang II. At the end of the ex-
periments, cells were washed three times in PBS, celldifferent approach in selectively overexpressing AT1 and
AT2 receptors in COS7 cells. Furthermore, a rat glomeru- layers were lysed, and protein concentrations of superna-
tants were adjusted to equal concentrations. Luciferaselar endothelial cell line that expresses AT1 and AT2 re-
ceptors, and PC12 cells that only bear AT2 receptors, and -galactosidase activities were measured with stan-
dard techniques. A ratio between luciferase and -galac-were studied in parallel. Our results unequivocally dem-
onstrate that Ang II activates NF-B through AT1 and tosidase activities was calculated, and data from unstimu-
lated control cells was assigned an arbitrary value of 1.0.AT2 receptors.
Transient transfections and reporter gene assays were
independently performed at least three times for each
METHODS
experiment.
Cell culture
Western blotsPC12 cells, a well-characterized rat adrenal pheochro-
mocytoma cell line, were obtained from the European For Western blot experiments, cells were stimulated as
appropriate. After washing in phosphate buffered salineCollection of Animal Cell Cultures (ECACC, Salisbury,
UK). Cells were grown in suspension cultures in Dulbec- (PBS), cells were lysed in 2% sodium dodecyl sulfate
(SDS), 60 mmol/L Tris-HCl (pH 6.8), 100 mmol/L dithi-co’s modified Eagle’s medium (DMEM; Gibco-BRL, Eg-
genstein, Germany) with 10% fetal calf serum (FCS) in othreitol (DTT), and the protein content was measured
by a modification of the Lowry method that is insensitive5% CO2 at 37C. In agreement with previous findings
[19], PC12 cells expressed only AT2-receptors by compet- to the concentrations of SDS and DTT. Protein concen-
trations were adjusted to 80 g/sample, and 5% glycerol,itive binding assays (data not shown). COS7 cells, origi-
nally established from African green monkey kidney, 0.03% bromophenol blue were added and samples were
boiled for five minutes. After centrifugation, superna-also were obtained from ECACC and grown as mono-
layers in DMEM with 10% FCS. Glomerular endothelial tants were loaded onto a denaturing 10% SDS-polyacryl-
amide gel. Rainbow markers (Amersham, Braunschweig,cells from rat (GERs) are a previously characterized cell
line that was established from Wistar rats [20]. These Germany) served as the molecular weight standards. After
completion of electrophoresis, proteins were electroblot-cells express AT1 and AT2 receptors [20]. GERs were
cultured in DMEM with 10% FCS. A clone of renal ted onto a nitrocellulose membrane in transfer buffer
(50 mmol/L Tris-HCl, pH 7.0; 30 mmol/L glycine, 20%tubular LLC-PK1 cells that expresses only AT1 receptors
[21] was used for some control experiments. methanol, 0.1% SDS). Filters were stained with Ponceau
S to control for equal loading and transfer. The blots
Transient transfections were blocked in 8% non-fat dry milk in PBS with 0.1%
Tween for one hour at room temperature. For the detec-COS7 cells were transiently transfected with expres-
sion vectors in which either the full-length rabbit AT1 tion of Ang II-receptor expression, specific polyclonal
rabbit anti-AT1 or AT2 receptor antibodies were used inreceptor [22] or the rat AT2 receptor [23] is under control
of a cytomegalovirus (CMV) promoter. Transfections a 1:500 dilution (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Lysates of LLC-PK1 cells, a tubular cell linewere performed in serum-free DMEM with Lipofectin
(Gibco-BRL). After 24 hours, cells were stimulated with that exclusively express AT1-receptors [21], served as an
additional control. For the detection of IB-, a rabbit107 mol/L Ang II (Sigma, Deisenhofen, Germany) in
the presence or absence of either 106 mol/L losartan polyclonal antibody (New England Biolabs, Beverly,
MA, USA) was used in a 1:1000 dilution. The secondary(gift of Merck, Sharp, and Dohm, Munich, Germany) or
PD123319 (Sigma). goat anti-rabbit IgG peroxidase–conjugated antibody
(BD Bioscience, Heidelberg, Germany) was used in a
NF-B transactivation assay 1:1000 dilution. The enhanced chemiluminescence sys-
tem (ECL) system (Amersham) was used for chemilumi-To test whether induced NF-B does indeed bind and
activate target genes, cells were transfected with 10 g nescence detection. To detect for small variations in pro-
tein loading and transfer, the membranes were washedof pNF-B-Luc, and the same amount of the plasmid
pSV--galactosidase in which the -galactosidase gene and re-incubated with a monoclonal antibody against
the housekeeping protein -actin (Sigma). Exposed filmsis under control of the SV40 promoter and enhancer.
The pNF-B-Luc reporter plasmid contains four tandem were scanned with Fluor-S multi-imager (Bio-Rad Labo-
ratories, Hercules, CA; USA), and data were analyzedcopies of the  enhancer fused to the herpes simplex
virus thymidine kinase promoter [24]. Activation results with the computer program MultiAnalyst. A ratio be-
tween the intensities of IB- and -actin bands wasin transcription of the luciferase gene. After transfection,
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calculated and cells without Ang II were arbitrarily as-
signed a relative value of 1.00. Western blotting experi-
ments were independently performed at least three times
with qualitatively similar results.
Gel shift assay
To investigate whether NF-B activation can be in-
duced by Ang II, gel shift assays were performed. Cells
were stimulated as appropriate with 107 mol/L Ang II
in the presence or absence of either losartan (106 mol/L) Fig. 1. Detection of angiotensin II subtype 1 (AT1; A) and AT2 (B)
receptor expression using Western blots incubated with specific antibod-or the same concentration of PD 123319. Some cells also
ies. (A) A band of approximately 45 kD specific for AT1 receptor isreceived p-Amino-Phe6-angiotensin II (Asp-Arg-Val-
detected in AT1 receptor transfected COS7 cells and rat glomerularTyr-Ile-p-Amino-Phe-Pro-Phe; Sigma), a specific agonist endothelial cells (GERs). Tubular LLC-PK1 cells known to express AT1
receptors served as positive control. Untransfected COS7 cells andfor the AT2 receptor [25]. After incubation, cells were
PC12 cells did not express AT1 receptors. (B) AT2 receptors are detecteddirectly washed twice in flasks with ice-cold PBS and
in GERs, PC12 cells, and COS7 transfected with AT2 receptor expres-were scraped off the bottom using a rubber policeman. sion plasmid, but not in untransfected COS7 cells. Re-incubation of the
blot with an antibody against -actin revealed that these differencesCells were centrifuged, pellets were transferred to Ep-
are not due to an uneven transfer of protein. This blot is representativependorf cups, and resuspended in buffer A composed of
of three independent experiments with qualitatively similar changes.
20 mmol/L HEPES, 0.1 mmol/L ethylenediaminetetra-
acetic acid (EDTA), 0.1 mmol/L egtazic acid (EGTA),
1 mmol/L DTT, 1 mmol/L phenylmethylsulfonyl fluoride extract preparation, and binding reactions) with qualita-
(PMSF), 1g/mL leupeptin, and 1 g/mL aprotinin. Cells tively similar results.
were lysed by the addition of 10% Nonidet-P40 for 10
seconds, lysates were immediately centrifuged for 30 sec- Statistical analysis
onds at 13,000 rpm, and pellets were resuspended in buf- All data are presented as means  SEM. Statistical sig-
fer B (30 mmol/L HEPES, 0.5 mol/L NaCl, 0.1 mmol/L nificance between different groups was first tested with
EDTA, 0.1 mmol/L EGTA, 1 mmol/L PMSF, 1 g/mL the non-parametric Kruskal-Wallis test. Individual groups
leupeptin, 1 g/mL aprotinin). After another centrifuga-
were subsequently tested using the Wilcoxon-Mann-Whit-
tion step at 13,000 rpm for five minutes, supernatants
ney test. A P value of 0.05 was considered significant.containing nuclear proteins were aliquoted, frozen, and
stored in liquid nitrogen. At total of 3.50 pmol of double-
strand consensus oligonucleotides for NF-B (5	AGTT RESULTS
GAGGGGACTTTCCCAGGC3	) was end labeled with AT1, AT2 receptor expression
[
-32P]ATP (3,000 Ci/mmol; Amersham) using T4 poly-
Angiotensin II subtype 1 and AT2 receptor expressionnucleotide kinase. Binding reactions were performed in
in our cells was first examined using Western blots ofgel shift binding buffer [10 mmol/L Tris-HCl, pH 7.5,
membrane lysates. A shown in Figure 1A, GERs and4% glycerol, 1 mmol/L MgCl2, 0.5 mmol/L EDTA, 0.5
COS7 cells transfected with the AT1 receptor plasmidmmol/L DTT, 50 mmol/L NaCl, 50 g/mL poly (dI-dC)
exhibited AT1 protein expression, but not untransfectedpoly (dI-dC)] with and without cold competitor oligonu-
COS7 cells and PC12 cells. Lysates of tubular LLC-PK1cleotides at room temperature for 30 minutes. OCT1
cells that express only AT1 receptors served as a positivedouble-strand consensus oligonucleotides (5	TGTCGA
control. Re-incubation of membranes with an antibodyATGCAAATCACTAGAA3	) were used as non-specific
against -actin revealed that protein was loaded ontocompetitors. For determination of the subunit composi-
each lane (Fig. 1A). On the other hand, GER, PC12tion of DNA-protein complexes, 2 g of a monoclonal
cells, and COS7 cells transfected with the AT2 receptormouse anti-p65/RelA antibody (Boehringer Mannheim,
plasmid exhibited AT2 receptor expression, but not un-Germany) or of a polyclonal gout anti-p50 antibody (Santa
transfected COS7 cells (Fig. 1B).Cruz Biotechnology) was added one hour before incuba-
tion with oligonucleotides. Reactions were stopped by
Reporter construct studiesaddition of loading buffer and samples were run on a
To test a functional role of Ang II-mediated NF-Bnon-denaturing 6% polyacrylamide gel. Gels were then
activation on gene transcription, a reporter plasmid con-exposed to x-ray films. Specific bands were scanned by
taining four tandem copies of the  enhancer was trans-densitometry as described above and binding of nuclear
fected into the various cell lines. As shown in Table 1,proteins from cells without Ang II was assigned a value
107 mol/L Ang II for 24 hours significantly stimulatedof 1.00. Gel shift analysis was independently performed
at least three times (separate cell stimulation, nuclear transactivation of the reporter construct in GER. This
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Table 1. Transcriptional activation of pNF-B-Luc
Luciferase
activity/
-galactosidase
activity
COS7/untransfected controls 1.00.0
COS7/untransfected  107 mol/L Ang II 0.90.4
COS7/AT1-receptor transfected controls 1.00.0
COS7/AT1-receptor transfected  107 mol/L Ang II 1.50.2a
COS7/AT2-receptor transfected controls 1.00.0
COS7/AT2-receptor transfected  107 mol/L Ang II 1.60.1a
GER controls 1.00.0
GER  10 ng/mL TNF- 1.60.1a
GER  107 mol/L Ang II 2.40.2a
GER  Ang II  106 mol/L Los 1.60.2c
GER  Ang II  106 mol/L PD 123319 1.50.2c
GER  Ang II  Los  PD 123319 1.10.1
PC12 controls 1.00.0
PC12  107 mol/L Ang II 1.50.1b
PC12  Ang II  106 mol/L Los 1.60.2a
PC12  Ang II  106 mol/L PD 123319 0.70.2c
N  3–6.
a P  0.05 versus unstimulated controls
b P  0.01 versus unstimulated controls
c P  0.05 versus Ang II only
effect was partly blocked by either losartan or PD 123319
suggesting involvement of both AT1 and AT2 recep-
tors. A combination of losartan and PD 123319 almost
completely blocked Ang II-induced transcription of the
pNF-B-Luc reporter plasmid (Table 1). COS7 cells trans-
fected with the AT1 or AT2 receptor expression con-
structs, but not mock-transfected cells, revealed trans-
activation of NF-B in the presence of Ang II (Table 1).
Finally, Ang II significantly induced gene transcription
by stimulating the  enhancer in PC12 cells that exclu-
sively expressed AT2 receptors (Table 1). This transcrip-
tional activity was attenuated by PD 123319 but not by
losartan (Table 1).
NF-B binding in vitro detected with EMSAs
The kinetic analysis of NF-B DNA-binding activity
Fig. 2. Nuclear factor-B (NF-B) binding in vitro as detected within vitro in various types of cells is demonstrated in Fig-
electrophoretic mobility shift assays (EMSAs). (A) Non-transfectedure 2. In AT1 and AT2 receptor transfected COS7 cells, COS7 cells showed no increase in NF-B binding to consensus oligonu-
a single dose of 107 mol/L Ang II induced binding of cleotides after stimulation with 107 mol/L angiotensin II (Ang II). (B)
In contrast, COS7 cells either transfected with AT1 or AT2 receptornuclear proteins to consensus oligonucleotides after 30
expression constructs revealed in increase in NF-B binding as earlyto 60 minutes (Fig. 2B), but not in untransfected COS7
as 30 minutes after stimulation with Ang II (107 mol/L). In addition,
cells (Fig. 2A). Even longer exposure of untransfected GERs treated with Ang II exhibit an increase in NF-B binding to
oligonucleotides. (C) Challenge of PC12 cells with 107 mol/L Ang IICOS7 cells with Ang II for 120 minutes failed to induce a
also induced NF-B activation. The specificity of the reactions wasgel shift (Fig. 2A). However, Ang II also induced NF-B
established using nuclear proteins from either Ang II-treated AT1 recep-
activation in GERs and PC12 cells (Fig. 2 B, C). tor transfected COS7 cells (A and B) or Ang II-stimulated PC12 cells
(C) with a 100-fold excess of unlabeled NF-B (competitor) or unrelatedAs shown in Figure 3A, Ang II-mediated NF-B bind-
OCT1 oligonucleotides (non-competitor). A densitometric analysis ofing in AT1 receptor transfected COS7 cells is attenuated experiments is shown in Table 2.
by 106 mol/L losartan, but not by the same concentration
of PD 123319. In contrast, 106 mol/L PD 123319 at-
tor antagonists was more effective than each drug alonetenuated NF-B binding in COS7 cells transfected with
(Fig. 3B). Finally, PD 123319 but not losartan inhibitedthe AT2 receptor expression plasmid (Fig. 3A). Both lo-
Ang II-mediated NF-B activation in PC12 cells (Fig. 3C).sartan as well as PD 123319 diminished NF-B activation
in GERs (Fig. 3B). A combination of AT1 and AT2 recep- To gain insight into subunit composition of NF-B
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Fig. 3. Effect of AT1 and AT2 receptor antagonists on NF-B binding in various cell lines. (A) Treatment of COS7 cells transfected with the AT1
receptor expression plasmid with 106 mol/L losartan (Los) almost completely attenuated NF-B binding induced by 107 mol/L Ang II. In contrast,
106 mol/L PD 123319 (PD) was without significant effect. Although 106 mol/L losartan somewhat reduced Ang II-mediated NF-B activation
in COS7 cells transfected with AT2 receptors, the same concentration of PD 123319 was more effective. (B) The AT1 receptor antagonist losartan
(106 mol/L Los) as well as the AT2 receptor blocker (106 mol/L PD) attenuated Ang II-induced NF-B binding to oligonucleotides in nuclear
protein preparations obtained from GERs. A combination of losartan and PD 123319 was more effective than each drug alone. (C) Only 106
mol/L PD 123319 (PD) attenuated NF-B binding in Ang II-treated PC12 cells whereas losartan (106 mol/L Los) was without effect. Specificity
of the reactions was confirmed with a 100-fold excess of unlabeled NF-B (competitor) or unrelated OCT1 oligonucleotides (non-competitor). A
densitometric analysis of experiments is shown in Table 2.
protein-DNA complexes, supershift experiments were subunits were also part of the NF-B obtained from Ang
II-treated GERs in which the peptide activates AT1 andperformed. Nuclear proteins prepared from Ang II-
treated PC12 cells and AT2 receptor transfected COS7 AT2 receptors (Fig. 4).
p-Amino-Phe6-angiotensin II (pNH2F-Ang II), whichcells revealed a supershift of complexes in the presence
of anti-p50 or anti-p65/RelA antibodies (Fig. 4). In accor- preferentially binds to AT2 receptors, was tested in addi-
tional studies. As demonstrated in Figure 5, 107 mol/Ldance with previous observations [26], supershifts were
incomplete possible because of steric hindrance. Su- pNH2F-Ang II for 30 minutes induced NF-B activation
in GERs, PC12 cells, and COS7 cells transfected withpershift experiments with nuclear extracts prepared from
AT1 receptor transfected COS7 cells revealed exactly the the AT2 receptor expression plasmid.
A densitometric analysis and statistical significance ofsome pattern indicating no major difference in NF-B
subunit composition (Fig. 4). Finally, p50 and p65/RelA EMSAs is provided in Table 2.
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Fig. 4. Supershift experiments to determine
subunit composition of NF-B. Nuclear pro-
teins obtained from AT1 or AT2 receptor
transfected COS7 cells, PC12 cells, and GERs
after stimulation with Ang II were incubated
with antibodies against p50 or p65 subunits
before addition of radiolabeled oligonucleo-
tides. Gel retardation (“supershift”) in the
presence of antibodies reveals that this sub-
unit is part of NF-B. There was not qualita-
tive difference in the supershifts of nuclear
proteins isolated from the various cell lines.
This indicates that both the p50 and p65 sub-
units are part of all NF-B complexes. This
EMSA is representative of two independent
experiments with qualitatively similar results.
Table 2. Densitometric quantification of nuclear factor-B
(NF-B) activation (EMSAs)
Arbitrary units
(controls1.00)
A. COS7 cells untransfected
Controls 1.000.00
30 minutes Ang II 1.020.02
60 minutes Ang II 0.980.10
120 minutes Ang II 1.110.03
B. COS7 cells AT1 receptor transfected
Controls 1.000.0
30 minutes Ang II 2.430.08b
60 minutes Ang II 1.230.06b
60 minutes Ang II  losartan 1.020.20c
60 minutes Ang II  PD 123319 2.510.80a
C. COS7 cells AT2 receptor transfected
Controls 1.000.00
30 minutes Ang II 2.490.30b
60 minutes Ang II 4.241.02a
60 minutes Ang II  losartan 2.940.12a
60 minutes Ang II  PD 123319 1.180.06c
D. GERs
Controls 1.000.00Fig. 5. p-Amino-Phe6-angiotensin II (pNH2F-Ang II) induces NF-B
30 minutes Ang II 1.270.15aactivation. COS7 cells transfected with AT2 receptors, GERs, and PC12
60 minutes Ang II 1.300.10acells were treated with 107 mol/L (pNH2F-Ang II), a peptide with a
60 minutes Ang II  losartan 1.200.08high affinity for AT2 receptors. pNH2F-Ang II activates NF-B in all
60 minutes Ang II  PD 123319 1.120.10three cell lines. This blot is representative of three independent experi-
60 minutes Ang II  losartan  PD 123319 1.010.03cments with qualitatively similar changes.
E. PC12 cells
Controls 1.000.00
30 minutes Ang II 1.350.07a
Ang II-mediated degradation of IB- 60 minutes Ang II 1.310.04a
60 minutes Ang II  losartan 2.000.11aTo further investigate potential molecular mechanisms
60 minutes Ang II  PD 123319 1.100.05c
for Ang II-mediated activation of NF-B, we studied
N  4–8.IB- expression using Western blots. Figure 6 shows a P  0.05 versus unstimulated controls
b P  0.01 versus unstimulated controlsIB- expression in AT1 receptor-transfected COS7 cells c P  0.05 versus cells treated with Ang II only(A), AT2 receptor-transfected COS7 cells (B), GERs
(C), and PC12 cells (D) 30 to 120 minutes after treatment
DISCUSSIONwith 107 mol/L Ang II. The membranes were reincu-
bated with an anti--actin antibody to control for loading Accumulating evidence suggests that Ang II exerts
and transfer of proteins. Ang II treatment reduces IB- proinflammatory properties in various tissues including
expression after 30 to 60 minutes. Densitometric analysis vessels and kidney [5–8, 27]. Treatment of immune and
non-immune mediated models of chronic nephropathyof independent experiments is given in Table 3.
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Fig. 6. Western blot for IB- expression in
AT1 receptor-transfected COS7 cells (A), AT2
receptor-transfected COS7 cells (B), GERs
(C), and PC12 cells (D) 30 to 120 minutes
after treatment with 107 mol/L Ang II. The
membranes were re-incubated with an anti-
-actin antibody to control for loading and
transfer of proteins. Ang II treatment reduces
IB- expression after 30 to 60 minutes. Den-
sitometric analysis of 3 to 4 independent ex-
periments is given in Table 3.
Table 3. Densitometric quantification of IB- expression For example, in cultured renal endothelial and mesangial
cells, Ang II induces chemokines such as MCP-1 andRelative IB- expression
normalized to -actin RANTES [10, 13]. Renal MCP-1 expression is partly
A. COS7 cells AT1 receptor transfected inhibited by AT1-receptor antagonists in mesangioproli-
Controls 1.000.00 ferative glomerulonephritis, diabetic nephropathy, uni-
30 minutes Ang II 0.950.09
lateral ureteral obstruction, and chronic transplant rejec-60 minutes Ang II 0.750.07a
120 minutes Ang II 0.410.15a tion [28, 30, 33, 34].
B. COS7 cells AT2 receptor transfected Nuclear factor-B is an important regulator of im-
Controls 1.000.00
mune responses by mediating transcription of chemo-30 minutes Ang II 0.810.09a
60 minutes Ang II 0.750.12a kines including MCP-1 and RANTES. Although initially
120 minutes Ang II 0.620.13b thought to be B cell specific [35], NF-B activity can be
C. GERs
induced in many cells by a wide range of different factors.Controls 1.000.00
NF-B exists in the cytoplasm in an inactive form associ-30 minutes Ang II 0.650.12a
60 minutes Ang II 0.670.06b ated with IB-. After phosphorylation, IB- is de-
120 minutes Ang II 0.610.04b graded and NF-B translocates into the nucleus [36].D. PC12 cells
Several in vitro and in vivo studies provide ampleControls 1.000.00
30 minutes Ang II 0.830.10a evidence that Ang II is a key mediator of NF-B activa-
60 minutes Ang II 0.510.06b tion [6, 9, 11, 31, 37]. Egido’s group was among the first120 minutes Ang II 0.840.08a
to show in elegant in vivo studies that ACE inhibitor
N  3 for GERs, N  4 for PC12 cells, N  5 for COS7 cells transfected
treatment reduces NF-B expression and macrophage/with either AT1 or AT2 receptors.
a P  0.05 versus unstimulated controls monocyte infiltration in a rabbit model of atherosclero-b P  0.01 versus unstimulated controls
sis, in immune complex nephritis, and, more recently, in
rats with overload proteinuria [6, 27, 31, 38]. Morrissey
and Klahr demonstrated that enalapril decreases NF-B
with angiotensin-converting enzyme (ACE) inhibitors in the kidney with unilateral ureteral obstruction [39].
reduces glomerular and tubulointerstitial macrophage/ Increased urinary protein excretion also increased NF-B
monocyte infiltration [27–32]. Ang II has chemoattrac- activation in rats after 5/6 nephrectomy and passive Hey-
mann nephritis [33]. This NF-B activation was paral-tant properties through local induction of chemokines.
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leled by an up-regulation of MCP-1 transcripts and was tagonist. Finally, the peptide pNH2F-Ang II with a high
affinity to AT2 receptors activates NF-B in PC12 cells,inhibited by the ACE inhibitor lisinopril [33]. Although
the inhibitory effects of ACE inhibitor on NF-B acti- GERs, and COS7 cells transfected with AT2 receptors.
In accordance with previous studies [11, 16], Ang II alsovation in the proteinuric models may be partly explained
by a reduction in proteinuria, there is also evidence that induces NF-B through AT1 receptors in GERs and
COS7 cells transfected with AT1 receptor expression plas-Ang II directly activates NF-B [33]. Mu¨ller and associ-
ates found that NF-B is a key mediator of inflammation mids. Limited supershift experiments provided evidence
that NF-B complexes are composed of p50 and p65in transgenic rats harboring both human renin and angio-
tensinogen genes [9]. Systemic infusion of Ang II into (RelA), the most common of the subunits. In accordance
with previous studies [26], supershift of bands was incom-naı¨ve rats activates NF-B in the kidney [40]. Interest-
ingly, an AT1 receptor antagonist diminished NF-B ac- plete suggesting steric hindrance. Since we have not per-
formed supershift experiments for all possible subunits,tivity in glomerular and tubular cells, whereas an AT2
receptor blocker attenuated only glomerular macro- we could not totally rule out that other subunits may have
a minor contribution to formation of NF-B activity.phages/monocyte infiltration and NF-B activation, sug-
gesting that both subtypes of Ang II receptors are in- However, there was no difference in composition of sub-
units in regard to AT1 or AT2 receptor activation.volved in NF-B activation [40].
Although there are convincing data that Ang II acti- Degradation of IB-was associated with NF-B acti-
vation, strongly suggesting that Ang II induces phos-vates NF-B in renal and cardiovascular cells, the sub-
type of Ang II receptor that is involved in this proin- phorylation and ubiquination of this inhibitory protein.
Previous in vivo studies in Ang II-infused rats as well asflammatory process remains incompletely understood.
Ang II binds to at least two different types of receptors, cell culture investigations with VSMC using specific an-
tagonists provided evidence that Ang II activates NF-BAT1 and AT2 [41–44]. AT1 receptors are responsible for
mediating many of the well-known stimulatory actions of through both the AT1 and AT2 receptors [16, 40]. How-
ever, relying only on receptor antagonists may be prob-Ang II on vasoconstriction, sodium intake, aldosterone
secretion, cell growth, and fibrogenesis [41]. In contrast, lematic because these agents are not totally specific. Fur-
thermore, there is cross-talking between AT1 and AT2the function of AT2 receptors is less clear. However,
recent evidence suggests that these receptors mediate receptors, and binding of Ang II to one subtype of recep-
tor may modulate expression of the other type [44]. Par-antiproliferative effects, apoptosis, and release of nitric
oxide [43, 44]. As a simplification, it has been assumed ticular AT2 receptors may be up-regulated in injured tis-
sue making an interpretation of findings difficult [43, 44].that AT2 receptor activation leads to principally opposite
effects compared to binding of Ang II to AT1 receptors, We therefore believe that our current approach with
selective reconstitution of AT1 or AT2 receptors providesand a “Yin-Yang” hypothesis of AT1/AT2 receptors has
been proposed [43, 44]. Therefore, we were surprised to compelling evidence that Ang II can indeed activate
NF-B through both receptor types. In this regard, thediscover that Ang II-stimulated induction of RANTES
in vitro and in vivo is attenuated by an AT2 receptor ability of the AT2 receptor to activate NF-B is impor-
tant. Recent studies of Ruiz-Ortega and coworkers foundantagonist but not by losartan [13]. Moreover, although
losartan lowered blood pressure induced by Ang II-infu- additional evidence in VSMC obtained from AT1 recep-
tor-deficient mice that Ang II activates NF-B in thosesion into naive rats, it failed to influence glomerular in-
filtration of macrophages/monocytes [13]. In contrast, in cells that only express AT2 receptors [45]. Angiotensin
III also activates NF-B in mesangial cells obtained fromvivo application of PD 123319 significantly attenuated
glomerular macrophage/monocyte influx without influ- AT1 knockout mice, further underscoring the ability of
this receptor to engage with proinflammatory signal trans-ence of blood pressure [13]. These data clearly suggest
that proinflammatory effects of Ang II can be transduced duction pathways [46]. AT1 and AT2 receptors interact
with different signal transduction intermediates [41–43].by AT2 receptors [13].
The present study provides clear evidence that binding Among other effectors, tyrosine kinase activation has
been described as a principal consequence of AT1 recep-of Ang II to AT2 receptors leads to activation of the
proinflammatory factor NF-B. Ang II stimulates NF-B tor activation whereas Ang II-binding to the AT2 recep-
tor subtype involves modification of phosphatase activityactivation in PC12 cells that only express AT2 receptors.
Furthermore, PD 123319 partly attenuates NF-B activa- [41–43]. It will be an important subject of future studies
to identify potential signal transduction mechanisms lead-tion in GERs that exhibit both AT1 and AT2 receptors.
Untransfected COS7 cells did not express Ang II recep- ing to NF-B activation through AT1 or AT2 receptors.
In vitro binding studies of NF-B may not necessarilytors and the peptide consequently failed to induce
NF-B. However, Ang II activates NF-B in COS7 cells reflect transcriptional activation of target genes by NF-B.
Investigating proinflammatory genes such as MCP-1 andtransfected with an AT2 receptor expression construct.
This activation was antagonized by an AT2 receptor an- RANTES may not be conclusive, because Ang II-medi-
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